Trial Profile
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALUR
- Sponsors Roche
- 24 Oct 2023 Results assessing baseline body mass index (BMI) associated with body weight gain from individual data of patients from J-ALEX, ALUR, ML29453 studies, presented at the 48th European Society for Medical Oncology Congress.
- 10 Sep 2019 Results presented at the 20th World Conference on Lung Cancer
- 10 Sep 2018 Status changed from active, no longer recruiting to completed.